- Home
- CFBK vs MOLN Comparison
CFBK vs MOLN Comparison
Compare CFBK & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CFBK | MOLN |
|---|---|---|
| Founded | 1892 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.1M | 154.2M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CFBK | MOLN |
|---|---|---|
| Price | $33.91 | $4.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $31.50 | $8.38 |
| AVG Volume (30 Days) | ★ 64.1K | 6.0K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | ★ 30.58 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.99 | N/A |
| Revenue Next Year | $9.09 | $374.07 |
| P/E Ratio | $43.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.10 | $3.41 |
| 52 Week High | $34.34 | $5.36 |
Technical Indicators
Market Signals| Indicator | CFBK | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 71.06 | 51.06 |
| Support Level | $28.40 | $3.94 |
| Resistance Level | N/A | $4.14 |
| Average True Range (ATR) | 0.90 | 0.07 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 66.67 | 73.08 |
Price Performance
Historical ComparisonAbout CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans, and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.